Roche’s Genentech reported superior Phase 3 interim results for its KRAS G12C inhibitor divarasib in previously treated non-small-cell lung cancer in the head-to-head Krascendo 1 trial. The company said divarasib improved overall survival and progression-free survival versus Amgen’s Lumakras and Bristol Myers Squibb’s Krazati, with no new safety signals. Genentech said it expects to submit the Phase 3 data to regulators and provide details at an upcoming medical meeting. The FDA granted divarasib breakthrough therapy designation in 2022 and orphan drug designation in 2026 for KRAS G12C NSCLC. The readout increases second-line competitive pressure in the KRAS G12C class, where head-to-head evidence is increasingly shaping how clinicians sequence targeted therapies after acquired resistance to first-generation agents.